Chemotherapy Induced Anemia
7
0
0
5
Key Insights
Highlights
Success Rate
83% trial completion
Treatment Research
8 treatments under study, led by Roxadustat
Research Leaders
7 sponsors active, led by Kyntra Bio
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
14.3%
1 terminated out of 7 trials
83.3%
-3.3% vs benchmark
43%
3 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (7)
A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy
Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)
A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
Research Network
Common Treatments
- Roxadustat2
- Recombinant Human Erythropoietin2
- Recombinant Human Erythropoietin Placebo1
- Sepo1
- And0171
Active Sponsors
- Kyntra Bio2
- Chugai Pharmaceutical2
- Affymax1
- Merck Sharp Dohme Llc1
- Astrazeneca1
Related Conditions
- Cancer1